Crossject Reappoints Key Members to Executive Board

Crossject, a specialty pharma company, has announced the reappointment of Patrick Alexandre and Isabelle Liebschutz to its executive board. Effective February 17, their terms have been renewed for four years by the supervisory board. This decision comes amid a streamlined restructuring focusing on the final registration stages of ZEPIZURE® with the FDA, a pivotal step in Crossject's U.S. marketing efforts.

Patrick Alexandre will continue as Chairman, alongside Isabelle Liebschutz, the Quality and Regulatory Affairs Director. Their leadership will be crucial as Crossject advances its needle-free ZENEO® auto-injector technology. With Olivier Giré's departure, the board plans to reinforce its presence in the U.S. market.

The company also emphasizes gratitude towards Olivier Giré for his contributions. The executives will rely on a team including Tony Tipton, Olivier Lacombe, Marianne Svensson, and Didier Morin to drive growth.